James Healy

About

Dr. Healy is a General Partner at Sofinnova Ventures. Dr. Healy has over 15 years of experience in biomedical research and development. He joined Sofinnova Ventures as a General Partner in 2000. Dr. Healy was an early investor and board member of Cellective (acquired by MedImmune), CoTherix (acquired by Actelion), Novacea (Nasdaq: NOVC), and InterMune (Nasdaq: ITMN). He also serves on the boards of directors of several private companies. In the pharmaceutical industry, he held a manufacturing position at Bayer Pharmaceuticals (Miles) and helped guide the discovery group at ISTA Pharmaceuticals prior to its initial public offering. Dr. Healy authored or co-authored numerous research articles and reviews, including three papers published in Nature. He began his private equity career at Sanderling. Dr. Healy earned B.A.s in Molecular Biology and Scandinavian Studies from the University of California at Berkeley, where he graduated with Distinction in General Scholarship, Honors, and r

Investment Focus

Location

Menlo Park, US